Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma Clinical Trial

Official title:

A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05521698
• Other study ID #: NCI-2022-06871
• Secondary ID: NCI-2022-06871Pe
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 15, 2024
• Est. completion date: May 15, 2027

Study information

• Verified date: January 2024
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized trial investigates the possible effect of apalutamide in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called epidermal growth factor receptor (EGFR) on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.

Description:

PRIMARY OBJECTIVE:

I. To compare epidermal growth factor receptor (EGFR) messenger ribonucleic acid (mRNA) expression measured by reverse transcriptase polymerase chain reaction (rt-PCR) in normal appearing urothelium adjacent to tumor (measured as a ratio relative to urothelium and lamina-propria specific markers) in participants treated with apalutamide therapy versus (vs.) untreated participants.

SECONDARY OBJECTIVES:

I. To determine the possible effect of apalutamide on EGFR expression (by rtPCR) in the subgroup of patients whose normal appearing urothelium adjacent to tumor expresses the AR (at least "1" by immunohistochemistry [IHC] score).

II. To correlate AR expression in adjacent urothelium (by IHC score) with EGFR expression by rtPCR in treated and untreated participants.

III. Comparison of toxicity of treatment group to untreated control.

EXPLORATORY OBJECTIVES:

I. Comparison of AR and EGFR (and possibly phosphorylated EGFR [pEGFR]) staining levels (low, moderate, high; by immunocytology) in pre-treatment vs. post-treatment bladder wash cytology.

II. To compare expression of direct androgen response gene (ADAR)-2 measured by rtPCR in normal appearing adjacent (to tumor) urothelium that does and does not express AR (by IHC), in apalutamide treated participants and untreated controls.

III. Ki-67 expression (by IHC) in normal appearing urothelium adjacent to tumor in treated vs. untreated participants.

IV. Subgroup analysis of Ki-67 expression in the AR+ subgroup. V. Differences in expression of AR, EGFR, pEGFR, and Ki-67 (by semi-quantitative IHC) in tumor in treated vs untreated participants.

VI. Comparison of demographics of two groups. VII. Change in EGFR expression by rt-PCR in tumor from treated vs. untreated participants.

VIII. Morbidities of treatment (breast tenderness, sexual or urinary side effects, seizure(s), depression, abnormal liver function tests [LFTs]).

IX. Comparison of pre vs. post intervention urinary biomarkers (CxBladderTM) in both groups, examining the 5 RNAs (by rtPCR) that make up the test, both as a group and each RNA separately.

X. Fibroblast growth factor receptor 3 (FGFR3) mutation analysis in deoxyribonucleic acid (DNA) extracted from formalin fixed paraffin embedded (FFPE) blocks from neighboring normal urothelium and tumor tissue in treated vs. untreated participants.

XI. Define changes in the tumor immune microenvironment pre- and post-apalutamide through liquid biopsies of blood and urine using high-dimensional flow cytometry and single cell transcriptomics.

XII. Analyze tumor (biopsy specimen) infiltrating CD8+ T-cells by single RNA Sequencing (scRNA-seq) and high dimensional spectral flow cytometry to evaluate TCF1/Tcf7 transcript levels, and perform IHC of CD44+, CD62L, and SLAMF6.

XIII. Other exploratory markers.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive apalutamide orally (PO) once daily (QD) on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of treatment is permitted in the absence of unacceptable toxicity. Patients undergo blood specimen collection at baseline and at time of TURBT.

ARM 2: Patients undergo TURBT on day 21. Patients undergo blood specimen collection at baseline and at time of TURBT.

After completion of study treatment, patients are followed up 20-30 days after TURBT.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: May 15, 2027
• Est. primary completion date: November 15, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biologic male adults ( >= 18 years old)

• Note: Because no dosing or adverse event (AE) data are currently available on the use of apalutamide in participants < 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.

• Have suspected non-muscle invasive bladder carcinoma (NMIBC) on clinic-based cystoscopy or imaging as viewed by an American Urological Association (AUA) board-certified urologist

• Have had cross sectional imaging of the abdomen and pelvis (computed tomography [CT] or magnetic resonance imaging [MRI] with or without contrast) within 6 months prior to enrollment with no signs of upper tract urothelial cancer (UC), invasive, nor metastatic disease

• Note: If adenopathy or upper tract abnormalities are identified, a negative biopsy and or ureteroscopy is required prior to enrollment

• Newly diagnosed or occasionally recurrent bladder cancer (BC)

• Note: Occasional recurrence is defined as =< 2 prior NMIBC episodes in the 18 months preceding cystoscopy where the index tumor was identified

• Participants with single and multiple tumor lesions

• Eastern Cooperative Oncology Group (ECOG) performance status =< 1

• Total bilirubin =< 1.5 x institutional upper limit of normal (note: in participants with Gilbert's syndrome, if total bilirubin is > 1.5 x upper limit of normal, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x upper limit of normal, participants may be eligible)

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 × institutional upper limit of normal

• Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2 × institutional upper limit of normal

• Urine Culture < 50,000 colonies/cc of 1 or more organisms (if found and treated and a confirmed negative culture obtained off antibiotics before study drug is started, they will be eligible)

• Serum Testosterone >= 300 ng/dL

• Thyroid stimulating hormone (TSH) within institutional normal

• White blood cell count (WBC) =< 0.5 × institutional lower limit of normal

• The effects of Apalutamide on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men who are having sex that can lead to pregnancy must use an acceptable form of contraception (vasectomy with the absence of sperm, sexual abstinence, condoms) throughout the course of the study

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Participants who have had a previous exposure to sex hormone (e.g., exogenous androgens) or anti-androgenic therapies (e.g., luteinizing hormone-releasing hormone [LHRH] agonists, LHRH antagonists, 5 alpha reductase-inhibitors, abiraterone or other anti-androgens) within 6 months of accrual

• Participants who are taking the following medications that increase seizure risks:

(e.g., clozapine, olanzapine, risperidone, ziprasidone),phenothiazine, antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine), bupropion, lithium, meperidine, pethidine, phenothiazine and tricyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline),mirtazapine, selective serotonin reuptake inhibitors (e.g., escitalopram, citalopram, fluoxetine), serotonin norepinephrine reuptake inhibitors (e.g., venlafaxine, desvenlafaxine, levomilnacipran), stimulants (e.g., amphetamines, methylphenidate), monoamine oxidase inhibitors (e.g., phenelzine, selegiline)

• Participants taking any form of anticoagulation (e.g., heparin, warfarin, lovenox, apixaban, rivaroxaban, dabigatran, edoxaban, betrixaban)

• Concurrent use of drugs in category X drug interactions with apalutamide

• Participants receiving any other investigational agents

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide

• History of prior or concurrent muscle invading UC, or concurrent prostatic urethral, urethral, or upper tract UC or non-urothelial bladder cancer

• History of radiation therapy to the pelvis, prostate or prostatic bed, or rectum

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Non-Muscle Invasive Bladder Urothelial Carcinoma

Intervention

Drug:
• Apalutamide
Given PO

Procedure:
• Biospecimen Collection
Correlative studies

Other:
• Questionnaire Administration
Ancillary studies

Procedure:
• Transurethral Resection of Bladder Tumor
Undergo TURBT

Locations

Country	Name	City	State
United States	National Cancer Institute Urologic Oncology Branch	Bethesda	Maryland
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	University of Wisconsin Carbone Cancer Center - University Hospital	Madison	Wisconsin
United States	University of Rochester	Rochester	New York
United States	University of Arizona Cancer Center - Prevention Research Clinic	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	AR and EGFR (and possibly phosphorylated EGFR [pEGFR]) staining levels	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Expression of direct androgen response gene (ADAR)-2	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Ki-67 expression	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Ki-67 expression in the AR+ subgroup	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Differences in expression of AR, EGFR, pEGFR, and Ki-67	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Demographics of two groups	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Change in EGFR expression in tumor from participants treated and untreated with apalutamide	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Morbidities of treatment	Breast tenderness, sexual or urinary side effects, seizure(s), depression, abnormal liver function tests (LFTs). Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Pre vs. post intervention urinary biomarkers	Comparison of pre vs. post intervention urinary biomarkers (CxBladderTM) in both groups, examining the 5 ribonucleic acids (RNAs) (by rtPCR) that make up the test, both as a group and each RNA separately.	Up to 28 days
Other	Analysis of fibroblast growth factor receptor 3 (FGFR3) in deoxyribonucleic acid (DNA)	Extracted from fixed paraffin embedded (FFPE) blocks from neighboring normal urothelium and tumor tissue in participants treated with or without apalutamide. Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Changes in the tumor immune microenvironment pre- and post-apalutamide	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Analysis of tumor (biopsy specimen) infiltrating CD8+ T-cells	Measured by single RNA sequencing (scRNA-seq) and high dimensional spectral flow cytometry to evaluate TCF1/Tcf7 transcript levels, and perform IHC of CD44+, CD62L, and SLAMF6. Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Other	Exploratory markers	Will be summarized by descriptive statistics such as rates and proportions and compared between participants treated with or without apalutamide using nonparametric tests such as the Kurskal-Wallis test.	Up to 28 days
Primary	The relative Epidermal Growth Factor Receptor (EGFR) expression level	Will be analyzed as a continuous variable. A two-sample Wilcoxon rank-sum test will be conducted to test whether there is significant differences of the log-transformed EGFR expression level measured by reverse transcriptase polymerase chain reaction (rt-PCR) in normal appearing urothelium adjacent to tumor (measured as a ratio relative to urothelium and lamina-propria specific markers) in participants treated with and without apalutamide.	Up to 28 days
Secondary	Effect of apalutamide on EGFR expression	A two-sample Wilcoxon rank-sum test will be conducted to compare the difference of EGFR expression in androgen receptor (AR) positive participants treated with and without apalutamide	Up to 28 days
Secondary	AR expression in adjacent urothelium with EGFR expression in participants treated with and without apalutamide	Pearson correlation and Spearman's rank correlation will be calculated between the AR expression and EGFR expression.	Up to 28 days
Secondary	Toxicity of participants treated with and without apalutamide	Descriptive statistics will be provided for these outcomes.	Up to 28 days